UNSPSC 51312204: Loratadine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H23ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7AJO3BO7QN, chemically known as 1-piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11h-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester but generally known as loratadine, which bears US NIH Compound Identifier 3957. European Medicines Agency schedules Loratadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08581MIG.

UNSPSC 51312204 Loratadine, a Commodity code, maps to state and local procurement of pharmaceutical products, though the recent opportunities posted under this code actually involve naloxone, safe drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products rather than loratadine specifically. State and local governments use this code family to procure medications and pharmaceutical supplies for public health programs, community health initiatives, pharmacy benefit management, and emergency response systems. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple states and municipalities. Seminole County, Florida, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the mix of jurisdictions and regional cooperative vehicles soliciting under related pharmaceutical codes.

Recent activity spans Florida, Texas, and Minnesota through cooperative arrangements. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 for MMCAP on January 20, 2026 (response due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local government facilities across Minnesota and Oregon, with awards effective July 1, 2026. Vendors responding to pharmaceutical solicitations at this tier must typically comply with cGMP and Drug Supply Chain Security Act requirements, maintain specified insurance coverage, provide NDC codes and product documentation, and accept administrative fees or performance penalties.